Status:

COMPLETED

A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects

Lead Sponsor:

Innovent Biologics (Suzhou) Co. Ltd.

Conditions:

Gout

Hyperuricemia

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

IBI128 (Tigulixostat) is a novel non-purine selective inhibitor of xanthine oxidase (XO). The XO inhibitors lower uric acid concentrations in serum by inhibiting the production of uric acid. This ia ...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Participants must be aged between 18 and 75 years old (inclusive, as of the time of signing the informed consent form), with no gender restrictions;
  • Body Mass Index (BMI) should fall within the range of 18.0 to 40.0 kg/m² (including both ends of the range);
  • Subjects must meet the 2015 ACR/EULAR classification criteria for the diagnosis of gout (refer to Appendix 4);
  • At the screening stage, subjects must have a blood uric acid level of ≥480 μmol/L;
  • Subjects must voluntarily sign the informed consent form and agree to strictly adhere to the requirements outlined in this protocol.
  • Exclusion criteria (brief):
  • History of allergy to any component of Tigulixostat;
  • Previous allergy or intolerance to Febuxostat;
  • Subjects who have taken uric acid lowering medications within 2 weeks prior to screening;
  • Subjects who experienced an acute gout flare-up within 4 weeks prior to screening or immediately before the first dose administration;
  • Subjects considered to have secondary gout (elevated serum uric acid due to causes other than renal insufficiency);
  • Subjects with a history of xanthinuria.

Exclusion

    Key Trial Info

    Start Date :

    July 10 2024

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    January 9 2025

    Estimated Enrollment :

    84 Patients enrolled

    Trial Details

    Trial ID

    NCT06501534

    Start Date

    July 10 2024

    End Date

    January 9 2025

    Last Update

    March 27 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Shanghai Fudan University HuaShan Hospital

    Shanghai, Shanghai Municipality, China, 200040